SCHEMBL4100336

SCHEMBL4100336

CC[C@H](C)CCCC[C]=O

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.35
ACE2 Q9BYF1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1410630 1.00 LMNA (0.35) LMNAACE2
SCHEMBL17143627 1.00 LMNA (0.35) LMNAACE2
SCHEMBL15326957 0.98 ACE2 (0.35) LMNAACE2
SCHEMBL8811887 0.98 ACE2 (0.35) LMNAACE2
SCHEMBL4575538 0.98 ACE2 (0.35) LMNAACE2
SCHEMBL4979534 0.98 ACE2 (0.35) LMNAACE2
SCHEMBL15326983 0.98 ACE2 (0.35) LMNAACE2
SCHEMBL1410664 0.98 ACE2 (0.35) LMNAACE2
SCHEMBL2431181 0.98 ACE2 (0.35) LMNAACE2
SCHEMBL294759 0.98 ACE2 (0.35) LMNAACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10711040-B2 Low substituted polymyxins and compositions thereof XELLIA PHARMACEUTICALS APS (DK) 2020-07-14 US claimed
US-10640536-B2 Polymyxins, compositions, methods of making and methods of use XELLIA PHARMACEUTICALS APS (DK) 2020-05-05 US claimed
EP-3166960-B1 LOW SUBSTITUTED POLYMYXINS AND COMPOSITIONS THEREOF XELLIA PHARMACEUTICALS APS (DK) 2019-08-07 EP claimed
EP-2943503-B1 POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE XELLIA PHARMACEUTICALS APS (DK) 2017-08-23 EP claimed
US-20170218024-A1 LOW SUBSTITUTED POLYMYXINS AND COMPOSITIONS THEREOF XELLIA PHARMACEUTICALS APS (DK) 2017-08-03 US claimed
US-20170137469-A1 POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS MONASH UNIVERSITY (AU) 2017-05-18 US claimed
EP-3166960-A1 LOW SUBSTITUTED POLYMYXINS AND COMPOSITIONS THEREOF Xellia Pharmaceuticals ApS (DK) 2017-05-17 EP claimed
CN-106414480-A POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS 莫纳什大学 2017-02-15 CN claimed
EP-3126376-A1 POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS Monash University (AU) 2017-02-08 EP claimed
WO-2016005223-A1 LOW SUBSTITUTED POLYMYXINS AND COMPOSITIONS THEREOF XELLIA PHARMACEUTICALS APS (DK) 2016-01-14 WO claimed
US-20160002296-A1 POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE XELLIA PHARMACEUTICALS APS (DK) 2016-01-07 US claimed
EP-2943503-A1 POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE Xellia Pharmaceuticals ApS (DK) 2015-11-18 EP claimed
WO-2015149131-A1 POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS MONASH UNIVERSITY (AU) 2015-10-08 WO claimed
CN-104918951-A POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE XELLIA PHARMACEUTICALS APS 2015-09-16 CN claimed
WO-2014108469-A1 POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE XELLIA PHARMACEUTICALS APS (DK) 2014-07-17 WO claimed
US-20090215677-A1 POLYMYXIN DERIVATIVES AND USES THEREOF NORTHERN ANTIBIOTICS LTD. (FI) 2009-08-27 US claimed
US-20230131376-A1 ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA UNIVERSITY OF NOTRE DAME DU LAC 2023-04-27 US disclosed
CN-114791470-A Method for detecting polymyxin in blood by high performance liquid chromatography-tandem mass spectrometry and application 北京和合医学诊断技术股份有限公司 2022-07-26 CN disclosed
US-8329645-B2 Polymyxin derivatives and uses thereof NORTHERN ANTIBIOTICS LTD. (FI) 2012-12-11 US disclosed
US-20090215677-A1 POLYMYXIN DERIVATIVES AND USES THEREOF NORTHERN ANTIBIOTICS LTD. (FI) 2009-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215677-A1 POLYMYXIN DERIVATIVES AND USES THEREOF C5, C9, C3AR1 LMNA 3052/4885ACE2 2482/4885
US-20160002296-A1 POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE C5, SGMS1, SGMS2 LMNA 1985/4885ACE2 2724/4885
US-20230131376-A1 ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA TLR4, TLR5, TLR1 LMNA 1078/4885ACE2 595/4885
US-10640536-B2 Polymyxins, compositions, methods of making and methods of use C5, HRH3, SGMS1 LMNA 1993/4885ACE2 2782/4885
US-20170218024-A1 LOW SUBSTITUTED POLYMYXINS AND COMPOSITIONS THEREOF TLR3, TLR4, TLR5 LMNA 1175/4885ACE2 2804/4885
US-10711040-B2 Low substituted polymyxins and compositions thereof TLR3, TLR4, TLR5 LMNA 1175/4885ACE2 2804/4885
US-20170137469-A1 POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS VIP, PEPD, NRDC LMNA 2991/4885ACE2 2139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.